Biotech entity
Department of Justice is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. Each story carries 10.3 original sources on average, compared with 3.6 for the broader beat in this window. Coverage clusters in pharma, which accounts for 3 of those 4, with the remainder spread across 1 other category.
Last mentioned: Mar 21, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Department of Justice is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. Each story carries 10.3 original sources on average, compared with 3.6 for the broader beat in this window. Coverage clusters in pharma, which accounts for 3 of those 4, with the remainder spread across 1 other category. The 166-day window averages about 0.2 stories each week. Their average consequence score of 6.8 runs above the beat's 6.1 for that window. This profile follows 4 Biotech stories mentioning Centers for Medicare & Medicaid Services across the period from March 4, 2026 to August 16, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 609 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Centers for Medicare & Medicaid Services. Shared-story counts are live from our verified record — not editorial picks.
Initial Expiration
The first six-month period ends, at which point CMS may choose to extend the moratorium.
Q4 2025 Earnings
Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
Moratorium Effective
CMS officially publishes the notice and the nationwide enrollment freeze begins immediately.
FDA 510(k) Submission
Premarket notification submitted for Lucent AD Complete diagnostic test.
CMS Reimbursement Milestone
CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
Data Review Concludes
CMS finishes a multi-year review of Medicare enrollment and claims data identifying high-risk trends.
OIG Fraud Warning
HHS OIG highlights billions in improper DME payments over the previous decade.
Assay Portfolio Expansion
Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.
Biotech and pharma teams evaluating cannabinoid-derived drugs face unsettled federal scheduling and reimbursement policy. MMJ's litigation could alter DEA and CMS pathways through stay, remand, or vacatur.
Source: finanznachrichten.de · pr-inside.com
The DOJ’s operation specifically targeted fraudulent genetic testing schemes, sending shockwaves through biotech and pharma reliant on lab services. A new Data Fusion Center and $48.6M in settlements signal aggressive federal interest in precision medicine marketing.
Source: wercfm.iheart.com · knst.iheart.com
The Centers for Medicare & Medicaid Services (CMS) has implemented a six-month nationwide freeze on new Medicare enrollments for seven categories of medical supply companies. This aggressive regulatory move, effective February 27, 2026, aims to curb systemic fraud and billions in improper payments within the DMEPOS sector.
Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
Centers for Medicare & Medicaid Services is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
